An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis

This observational study tracks people with EGFR-mutated non-small cell lung cancer (NSCLC) who have brain metastases and are receiving furmonertinib — a third-generation targeted therapy — in real-world clinical practice, to see how well it works and how safe it is outside of a controlled trial setting. **You may be eligible if...** - You are 18 or older - You have advanced non-small cell lung cancer confirmed by biopsy with an EGFR mutation (exon 19 deletion or L858R, with or without T790M) - You have brain metastases that have been confirmed by imaging (MRI or CT) and have not yet been treated - You are about to start furmonertinib as your next treatment - You are in good enough health to take oral furmonertinib (ECOG 0-2) **You may NOT be eligible if...** - You have previously received any third-generation EGFR inhibitor (such as osimertinib) - You have a known allergy to furmonertinib - You have already been treated for your brain metastases Talk to your doctor to see if this trial is right for you.